Vanguard Capital Management
ZVRA icon

Vanguard Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Vanguard Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.8M Buy
2,638,910
+169,582
+7% +$1.89M ﹤0.01% 2093
2026
Q1 		$23M Buy
+2,469,328
New +$22.3M ﹤0.01% 2262

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Vanguard Capital Management's ZVRA Position: Q2 2026 in Review

Vanguard Capital Management increased its Zevra Therapeutics (ZVRA) stake by 6.9% in Q2 2026, buying an estimated $1.89M and bringing the position to 2,638,910 shares worth $37.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2093.

Vanguard Capital Management first reported a position in ZVRA in Q1 2026 and has held it in 2 quarters since. 156 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Vanguard Capital Management held 2,638,910 shares of Zevra Therapeutics worth $37.8M as of Q2 2026.
  • Vanguard Capital Management bought 169,582 Zevra Therapeutics shares in Q2 2026, an estimated $1.89M.
  • Zevra Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2093 holding.
  • Vanguard Capital Management first reported a position in Zevra Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 156 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.